Drugs / Belviq
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01880502 | Jun → Jul 2013 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03353220 | Jan 2018 → Feb 2020 | — | Columbia University | Terminated | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Belviq | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01880502 ↗ |
| Action | Activate | “lorcaserin (LOR), a 5HT2cR agonist that targets proopiomelanocortin (POMC) neurons” PMID 36897161 ↗ Aug 2023 |
| Route | Oral | “Belviq is an oral drug” NCT03353220 ↗ |